Patent intelligence · US
US 11123360
Oligonucleotides to treat eye disease
Oligonucleotides to treat eye disease
Patent details — US 11123360
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 21, 2021
- Expiration
- Sep 16, 2041
- Applicant
- ProQR Therapeutics II B.V.
- Claims
- 17
- CPC classes
- A61K, A61K31/7125, A61K9/0048, A61P
Quick answer
US 11123360 (Oligonucleotides to treat eye disease) is held by ProQR Therapeutics II B.V.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/7125, A61K9/0048, A61P, A61P27/02
More from ProQR Therapeutics II B.V.
Related pharmaceutical patents in our USPTO index.
-
US 12275937
Stereospecific linkages in RNA editing oligonucleotides
granted -
US 12203072
Chemically modified single-stranded rna-editing oligonucleotides
granted -
US 12180471
Antisense oligonucleotides for the treatment of Stargardt disease
granted -
US 12018257
Single-stranded RNA-editing oligonucleotides
granted -
US 11920132
Oligonucleotide therapy for Leber congenital amaurosis
granted -
US 11851656
Chemically modified single-stranded RNA-editing oligonucleotides
granted -
US 11649454
Single-stranded RNA-editing oligonucleotides
granted -
US 11479771
Antisense oligonucleotides for the treatment of eye disease
granted
Frequently asked questions
What is US patent 11123360?
US 11123360 (Oligonucleotides to treat eye disease) is held by ProQR Therapeutics II B.V.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11123360?
ProQR Therapeutics II B.V. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 19 pharmaceutical patents for this assignee.
When does US 11123360 expire?
Our index shows an expiration date of Sep 16, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.